REDWOOD CITY, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Dextera Surgical Inc. (Nasdaq:DXTR), manufacturer of the smallest-profile and most maneuverable articulating surgical stapler platform on the market for minimally invasive surgery, today announced the company has entered into a marketing and distribution agreement with B. Braun Surgical S.A. to bring Dextera’s MicroCutter 5/80 surgical stapler to surgeons in Spain.
B. Braun Surgical S.A. is the distribution arm of the B. Braun Aesculap Group headquartered in Tuttlingen Germany, a global leader in developing, manufacturing and marketing innovative medical products and services in the healthcare industry. B. Braun Surgical S.A. holds as well the Center of Excellence (CoE) within the Group for Closure Technologies, leading the global responsibility for business operations in surgical sutures, surgical meshes and stapling devices.
Under the terms of the agreement, B. Braun Surgical S.A. will have exclusive rights to distribute the MicroCutter in Spain through B. Braun Surgical S.A.’s laparoscopic unit. B. Braun Surgical S.A. has an extensive network of direct and indirect sales representatives in Spain who focus on surgeons performing minimally invasive surgical procedures.
The MicroCutter 5/80, with its unique design and ability to enable minimally invasive surgery, fills an important gap that complements B. Braun’s comprehensive portfolio of surgical devices, which includes the EinsteinVision® 3D camera system, the Caiman® Advanced Bipolar Seal and Cut Technology and other flagship laparoscopic instruments.
“This agreement with B. Braun Surgical S.A. in Spain is an important and strategic first step in the expansion of our worldwide presence with the MicroCutter,” said Julian Nikolchev, president and CEO of Dextera Surgical. “B. Braun Surgical S.A. brings a wealth of experience in laparoscopic and thoracoscopic surgical instruments to leading surgeons in Spain, which makes the company a perfect partner to continue to advance minimally invasive surgery in Europe and around the world.”
MicroCutter Indication Information
The MicroCutter 5/80 Stapler is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine, and the transection of the appendix. The MicroCutter 30 White Reload has application in vascular tissue.
About Dextera Surgical
Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.
The company's signature proprietary technology, the MicroCutter 5/80 Stapler, is the world's first and only five-millimeter surgical stapler that articulates to 80 degrees in each direction. As the smallest-profile articulating stapler available today, the MicroCutter 5/80 Stapler may reduce the amount of dissection and tissue handling required to position the stapler in confined spaces, enabling access to difficult-to-reach anatomy. The cartridge-based device's small size and wide articulation range are designed to enhance the surgeon's access and visualization at the surgical site and to mitigate limitations on the advancement of minimally invasive surgical approaches created by larger stapling devices.
Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.
The statements in this press release regarding the belief that the MicroCutter 5/80 will facilitate and enhance minimally invasive surgeries for thought leaders across Spain is a "forward-looking statement." There are a number of important factors that could cause Dextera Surgical’s results to differ materially from those indicated by this forward-looking statement, including: that Dextera Surgical may not be successful in its efforts to make the improvements necessary to its enhanced MicroCutter device due to unanticipated technical or other difficulties; risks inherent with respect to regulatory matters; as well as other risks detailed from time to time in Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2016, Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, under the caption “Risk Factors.” Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.
Last updated on: 18/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.